428 related articles for article (PubMed ID: 26390342)
1. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
Sumi NJ; Kuenzi BM; Knezevic CE; Remsing Rix LL; Rix U
ACS Chem Biol; 2015 Dec; 10(12):2680-6. PubMed ID: 26390342
[TBL] [Abstract][Full Text] [Related]
2. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
Poratti M; Marzaro G
Eur J Med Chem; 2019 Jun; 172():143-153. PubMed ID: 30978559
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
4. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
5. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
6. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Zhao B; Burgess K
Chem Commun (Camb); 2019 Feb; 55(18):2704-2707. PubMed ID: 30758029
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Mayer EL
Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
[No Abstract] [Full Text] [Related]
9. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
Braal CL; Jongbloed EM; Wilting SM; Mathijssen RHJ; Koolen SLW; Jager A
Drugs; 2021 Feb; 81(3):317-331. PubMed ID: 33369721
[TBL] [Abstract][Full Text] [Related]
11. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
12. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Sheng J; Kohno S; Okada N; Okahashi N; Teranishi K; Matsuda F; Shimizu H; Linn P; Nagatani N; Yamamura M; Harada K; Horike SI; Inoue H; Yano S; Kumar S; Kitajima S; Ajioka I; Takahashi C
Hepatology; 2021 Oct; 74(4):1971-1993. PubMed ID: 33931882
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
16. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment.
Li J; Jiang J; Wu J; Bao X; Sanai N
Clin Pharmacol Ther; 2021 Feb; 109(2):494-506. PubMed ID: 32799335
[TBL] [Abstract][Full Text] [Related]
18. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
[TBL] [Abstract][Full Text] [Related]
19. Recent advances of highly selective CDK4/6 inhibitors in breast cancer.
Xu H; Yu S; Liu Q; Yuan X; Mani S; Pestell RG; Wu K
J Hematol Oncol; 2017 Apr; 10(1):97. PubMed ID: 28438180
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle inhibitors make progress.
Brower V
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25006194
[No Abstract] [Full Text] [Related]
[Next] [New Search]
